Hepatitis C virus DNA vaccines: a systematic review

Ali Shayeghpour1†, Roya Kianfar2†, Parastoo Hosseini3,4, Mehdi Ajorloo5,6, Sepher Aghajanian1, Mojtaba Hedayat Yaghoobi7, Tayebeh Hashempour8 and Sayed-Hamidreza Mozhgani9,10*

Abstract

Background: Vaccination against HCV is an effective measure in reduction of virus-related public health burden and mortality. However, no prophylactic vaccine is available as of yet. DNA-based immunization is a promising modality to generate cellular and humoral immune responses. The objective of this study is to provide a systematic review of HCV DNA vaccines and investigate and discuss the strategies employed to optimize their efficacies.

Methods: MEDLINE (PubMed), Web of Science, Scopus, ScienceDirect, and databases in persian language including the Regional Information Centre for Science & Technology (RICeST), the Scientific Information Database and the Iranian Research Institute for Information Science and Technology (IranDoc) were examined to identify studies pertaining to HCV nucleic acid vaccine development from 2000 to 2020.

Results: Twenty-seven articles were included. Studies related to HCV RNA vaccines were yet to be published. A variety of strategies were identified with the potential to optimize HCV DNA vaccines such as incorporating multiple viral proteins and molecular tags such as HBsAg and Immunoglobulin Fc, multi-epitope expression, co-expression plasmid utilization, recombinant subunit immunogens, heterologous prime-boosting, incorporating NS3 mutants in DNA vaccines, utilization of adjuvants, employment of less explored methods such as Gene Electro Transfer, construction of multi- CTL epitopes, utilizing co/post translational modifications and polycistronic genes, among others. The effectiveness of the aforementioned strategies in boosting immune response and improving vaccine potency was assessed.

Conclusions: The recent progress on HCV vaccine development was examined in this systematic review to identify candidates with most promising prophylactic and therapeutic potential.

Keywords: Hepatitis C Virus, Immunogenicity, Systematic review, DNA vaccines, RNA vaccines, Immune response

Background

Hepatitis C virus (HCV) particle contains a single-stranded positive-sense RNA genome that encodes a single polyprotein which is further processed to generate at least 11 polypeptides/proteins, including three structural proteins (core, and envelope proteins E1 and E2), a small polypeptide named p7, the novel F protein, and six nonstructural (NS) proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) [1, 2]. At present, infection with HCV poses a significant threat to global health and is associated with significant mortality and morbidity worldwide. Approximately, 184 million individuals were infected by the virus by 2005, many of which may progress to cirrhosis, liver fibrosis, and hepatocellular carcinoma if left untreated [3]. It was previously estimated that three to four million people are infected every year with about 90% being unaware of their chronic infection. This had led to projected estimations of up to 30 million carriers in China by 2050 if large-scale screening programs were not to be implemented [4, 5]. In line with this, almost all of...
10 million chronic HCV carriers in Pakistan are unidentified, despite projection of a decreasing trend for the incidence of HCV infection [4, 6]. Therefore, considering the global burden of the infection, financial burden of directly acting antiviral agents, risk of reinfection, and higher risk of hepatocellular carcinoma in previously infected individuals even after sustained virologic response [4, 7, 8], there is a strong incentive to develop prophylactic vaccines even with partial protection against HCV.

A novel vaccine for HCV would be able to significantly reduce the incidence of HCV infection and has the potential to achieve global control and possibly lead to the eradication of the virus. However, several barriers exist to development of such preventive measures including limited host tropism and full-length genome HCV culture in most cell lines, virus diversity, difficult identification of at-risk populations for testing vaccines, and the incomplete understanding of immune system and its protective response against HCV [9, 10]. Among the established vaccine types, a number of experimental nucleic acid-based vaccines are being developed which are mostly directed at inducing antibodies and cytotoxic T lymphocyte (CTL) responses against the non-structural proteins and envelope proteins of the virus.

A variety of elements have been implicated in adjusting the effectiveness of DNA vaccines such as host, target antigenic region, prime-boost approaches, presence or absence of adjuvant, dosage and immunization schedule which can be utilized to boost immunization outcomes [11]. To improve the effectiveness of the vaccines, several studies have been carried out to assess the efficacy of a variety of modifications in improving vaccine potency. In this regard, the use of truncated form of the highly immunogenic NS3 protein [12], taking advantage of vector-based and plasmids vaccines [13, 14], exploring prime-boost regimens with DNA and recombinant virus vaccines [15], utilizing multi-epitope DNA and peptide vaccines and novel techniques such as Gene Electrotransfer [16, 17], development of multigenotype vaccines [18], and inclusion of genetic adjuvants such as Human and avian hepatitis B virus (HBV) core antigen (HBcAg) [19], perforin (PRF) [20], heat shock protein gp96 [21], CC-chemokine ligand 20 (CCL20) gene [22], Interleukin-12 (IL-12) [23], IL-23, granulocyte-monocyte colony stimulating factor (GM-CSF) [24], etc. have been explored in previous studies.

In this study, a systematic review of the existing literature over the last 20 years was conducted to assess the efficacy, effectiveness, immunogenicity, and safety data regarding HCV nucleic acid vaccines on laboratory animals. We have also outlined a number of approaches to improve vaccine efficacy, in hopes that this work will aid future studies in development of prophylactic and therapeutic vaccines against HCV.

### Methods

#### Search strategy

This study reviewed published articles in English and Persian language between 2000 and 2020. International databases including MEDLINE (PubMed), Web of Science, Scopus and ScienceDirect as well as persian repositories including the Regional Information Centre for Science & Technology (RICeST), the Scientific Information Database and the Iranian Research Institute for Information Science and Technology (IranDoc) were explored to find relevant reports on HCV nucleic acid vaccines from 2010 to 2020. The keywords and terms used to find articles relevant to DNA immunization included ‘Hepatitis C Virus and DNA vaccine’, ‘HCV DNA vaccine and development’, ‘HCV DNA vaccine and Adjuvant’, ‘HCV DNA vaccine and Antigenic target’, ‘HCV DNA vaccine and Immunogenicity’, ‘HCV DNA vaccine and efficiency’. For RNA-based immunization the following keywords were used: ‘Hepatitis C Virus and RNA vaccine’, ‘Hepatitis C Virus and RNA and vaccine’, ‘HCV RNA vaccine and development’, ‘HCV RNA vaccine and Adjuvant’, ‘HCV RNA vaccine and Antigenic target’, ‘HCV RNA vaccine and Immunogenicity’, and ‘HCV RNA vaccine and efficiency’.

In addition, relevant cited references in the original articles were examined to include articles which were not indexed by the aforementioned databases. References and their abstracts were saved and reviewed using EndNote X9.1 and EndNote 20 reference manager software (Clarivate Analytics, USA).

#### Selection criteria and data extraction

Following systematic search, studies were screened to select original research articles focusing on HCV infection, HCV DNA vaccines and their immunogenicity and efficacy. Reports were removed if the individuals in the studies were infected with other genera of hepaciviruses or if the study was based on non-DNA vaccines. Studies without full texts or in languages other than Persian or English were also excluded.

Two independent reviewers screened and evaluated the included studies to extract the following data: title, abstract, main text, authors, country of origin, the host, target antigenic region, number of boosters, presence or absence of adjuvant, dosage, and immunization.

### Results

The preliminary search for DNA-based vaccine development identified 853 papers in Web of Science, 474 papers in MEDLINE (PubMed), 1381 papers in Scopus, 678 papers in ScienceDirect, 38 papers in Iranian databases,
and 12 articles from manual search. After omission of 1678 duplicate papers, 1758 articles were surveyed for eligibility, out of which 27 articles were included. The search for RNA vaccines yielded no relevant studies, alluding to the lack of research on RNA vaccines for HCV. Therefore, a total of 27 records were found eligible for this systematic review (Fig. 1). A summary of the prominent included studies is available in Table 1.

**HCV vaccine target sequence**

*Protein selection*

Previous studies have focused on several viral proteins and their combinations in generating adequate immune response for HCV vaccine development. Among the proteins assessed for vaccine utilization, plasmids encoding HCV NS3, NS4, NS5, core, and the envelope proteins E1/E2 as their full or truncated isoforms, or fractured peptides consisted the majority of the previous works. A summary of these studies is provided below.

The expression of partial length of NS3 gene, which encodes immunogenic epitopes (1095–1379 aa) was demonstrated to be capable of induction of significant levels of total antibody, IgG2a subclass antibody, Interferon (IFN)-γ, Interleukin (IL)-4 and proliferation assay [12]. Furthermore, incorporation of NS4A in NS3-based genetic immunization using a cloned full-length genotype NS3/4A gene resulted in increased expression of NS3 and higher levels of NS3-specific antibodies (10- to 100-fold) and IgG2a/IgG1 ratio (420 vs. 3) in humoral responses compared to NS3 gene, demonstrating a favorable Thelper 1-skewed response. In line with this, low dose i.m. (10 mg) immunization with the NS3/4A gene inhibited the growth of an NS3/4A-expressing tumor cells in vivo, whereas immunization using the NS3 gene alone or NS3 protein did not. Furthermore, a three to four 4 mg dose of a NS3/4A plasmid administered using a gene gun primed CTL at a precursor frequency of 2–4%, which inhibited the growth of NS3/4A-expressing tumor cells in vivo. further demonstrating the effectiveness of multiprotein DNA vaccines [25]. The direct immunogenicity of NS3/4A plasmids were also examined by Ahlen et al. and Behzadi et al. whom reported removal of transiently transgenic hepatocytes by T cells in liver and significant cell-mediated immune responses with a DNA vaccine encoding HCV-3a NS3/NS4A in C57BL/6 mice, respectively [26, 27].

The safety concerns regarding RNA helicases and their disruption of cellular functions and their possible role in development of cancer had let Ratnoglik et al. construct plasmids encoding mutated NS3 protein without serine protease and helicase catalytic activity to replace their bioactive counterpart in vaccine.

---

**Fig. 1** Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram for search and screening strategy.
| Row | Author(s) | Year | Host | Genomic region for design | Route | Prescribed number | Adjuvant | Laboratory method | Efficiency | References |
|-----|-----------|------|------|---------------------------|-------|-------------------|----------|-------------------|------------|------------|
| 1   | Pouriayevali, M. H., et al | 2019 | BALB/c mice | NS3 gene sequence (1095-1380aa) | ID | three doses in two-week intervals | Listeriolysin O (LLO) | PCR, western blot, lymphocyte proliferation, cytotoxicity, and cytokine levels assays | Enhancement of total IgG in mixed responses with Th1 dominancy | [56] |
| 2   | Lee, H et al | 2017 | BALB/c mice | NS3 to NS5A | IM | three doses in two-week intervals | murine IL-28B | Body weight change, necropsy, hematological and serum biochemical evaluation, LD50 determination, IFN-γ ELISpot assay | Increased NS3,4, and 5 IFN-γ spots in ELSpot assay | Murine IL-28B resulted in more than twice NS3/4A specific IFN-γ spots per million splenocytes | [75] |
| 3   | Pouriayevali, M. H., et al | 2016 | BALB/c mice | NS3 gene (1095—1379 aa) | ID | four doses in two-weeks intervals | N/A | RNA Extraction and cDNA Synthesis, total and subtypes of IgG antibody assay, cell proliferation assay, western blot and ELISPOT | Induced significant levels of total antibody, IgG2a, IFN-γ and IL-4 | [12] |
| 4   | Levander, S., et al | 2016 | C57BL/6 J mice | NS3/4A-stork-HBcAg | IM | one to five times with doses of 50, 5, 0.5, 0.05, and 0.005 µg | HBcAg | In vitro transcription and translation assay, Transient transfection, western blot and ELISPOT assay | Increased production of IFN-γ, IL-2 and IL-4 | [19] |
| 5   | Behzadi, M. A., et al | 2016 | C57BL/6 mice | NS3/NS4A | IM | Three injection, 2 weeks apart | Freund's adjuvant, MPL | Flow cytometry, T helper frequency using cell staining | Increased production of Th1/Th2 and T CD8+ cells | [26] |
| 6   | Yazdanian, M., et al | 2015 | BALB/C mice | HBsAg and core (amino acids 2–120) | IV | Three doses | pluronic acid (F 127) | CTL assay, SDS-PAGE and western blotting for plasmid expression, Antigen specific proliferation assay, and ELSpot assay | Shifting the immune responses pathway to Th1 by enhancing the IFN-γ-cytokine level | [1] |
| 7   | sun, w., et al | 2015 | BALB/C mice | HCV E2 with an immunoglobulin Fc fusion tag | SC | Approximately Four doses in two-weeks intervals | CpG ODN/Quil A | ELISA assay, Lymphocyte Proliferation Assay, Immunofluorescence Assay and HCVpp Neutralization Assay | Enhancement of E2-specific humoral and cellular immune response | [46] |
| Row | Author(s) | Year | Host | Genomic region for design | Route | Prescribed number | Adjuvant | Laboratory method | Efficiency | References |
|-----|-----------|------|------|---------------------------|-------|-------------------|----------|-------------------|------------|------------|
| 8   | Pishraft Sabet, L., et al | 2015 | CB6F1 mice | Core(132–142), E2(412–426), NS3(1073–1081), NS5B(2727–2735) | IM    | three times at 2-week intervals, heat shock protein gp96 (NTgp96) | flow cytometry and ELISA | Induction of T-cell and antibody responses | [21] |
| 9   | Masalova, O. V., et al | 2015 | DBA/2 J mice | NS3–NS5B | IM    | three times with an interval of 2 weeks | pcGM-CSF | ELISA, ELISpot | Enhancement of humoral and cellular immune response | [32] |
| 10  | Gummow, J., et al | 2015 | C57BL/6 mice | nonstructural (NS) proteins (B, 4A, 4B, and 5B) | ID    | either two or three doses at 2-week intervals | perforin | Cell culture, ELISpot, T-cell proliferation assay, Flow cytometry and Western blot | Enhancement of TNF-a-producing CD4+ and CD8+ T-cells | [50] |
| 11  | Hartoonian, C. et al | 2014 | BALB/C mice | Core protein | SC    | three times in 2-week intervals | Macrophage Inflammatory Protein 3-beta (MIP-3beta) | ELISpot and cytotoxic Granzyme B release assays, ELISA | Enhancement of IFN-gamma/IL-4 and anti-core IgG2a/IgG1 ratio, lymphoproliferation, strong cytolytic GrzB release | [55] |
| 12  | Hartoonian, C. et al | 2014 | BALB/c mice | Core protein | SC    | three times in 2-week intervals | CC-chemokine ligand 20 (CCL20) | ELISA/ELISpot and cytotoxic Granzyme B (GrzB) release assays | Enhancement of core specific IFN-c/IL-4 ratio, IL-2 release, IFN-c and the core-specific serum total IgG and IgG2a/IgG1 ratio were significantly higher when the pCCL20 was co-inoculated | [22] |
| 13  | Ahlen, G. et al | 2014 | BALB/c (H-2d) and/or C57BL/6 J (H-2b) mice | NS3/4A | gene gun delivery to the skin or by IM one, two, three or four times at monthly interval | N/A   | ELISpot, RMA-S stabilization assay and cytotoxicity assay | Production of NS3/4A-specific T cells in vitro | [76] |
| Row | Author(s)       | Year | Host            | Genomic region for design | Route | Prescribed number | Adjuvant | Laboratory method                                      | Efficiency                                                                 | References |
|-----|----------------|------|-----------------|----------------------------|-------|-------------------|----------|-------------------------------------------------------|----------------------------------------------------------------------------|------------|
| 14  | Gorzin, Z. et al | 2013 | C57BL/6 mice    | non-Structural Protein 2 (NS2) | IM    | three times with an interval of 2 weeks | IL-12    | ELISA, Cytokine secretion assay, MTT                 | Enhancement of CTL response, interferon-γ production, and lymphocyte proliferation compared to negative control | [77]       |
| 15  | Wada, T. et al  | 2013 | C57BL/6 mice    | structural protein (CN2), non-structural protein (N25) | IP    | three times at 48-h intervals | N/A      | cytotoxicity assay, ELISPOT assay, Generation of CTL effector cells and cytotoxicity assay, Histopathological examination and ELISA | significant decrease in the expression of HCV protein in mice administered the N25 DNA vaccine and improvement of pathological changes in the liver by N25 DNA vaccine | [78]       |
| 16  | Naderi, M. et al| 2013 | C57BL/6 mice    | NS3                        | IM    | Three times       | IL-12    | RT-PCR, western blot, ELISA, Lymphocyte proliferation assay | Production of significant levels of both IL-4 and interferon (IFN)-γ and enhancement of cytotoxicity and lymphocyte proliferation responses of vaccinated mice | [23]       |
| 17  | Holmstorm, F. et al | 2013 | C57BL/6 J mice  | Optimized Synthetic Codon of NS5A | IM    | One to three times at monthly intervals | N/A      | ELISA, western blot, ELISPOT assay, cytotoxicity assay and RMA-5 stabilization assay | Production of high Ab levels, IFN-γ and lytic cytotoxic T cells | [79]       |
| 18  | Park, S. et al  | 2010 | monkeys as the naive group | E2                          | IM    | 6 times at the indicated months | IL-7     | ELISA, ELISPOT assay                                 | Enhancement of antibody responses specific for HCV E2 protein and specific T cell responses by codelivery of HIL-7 DNA | [80]       |
| Row | Author(s)          | Year | Host                              | Genomic region for design | Route | Prescribed number | Adjuvant | Laboratory method | Efficiency                                                                 | References |
|-----|--------------------|------|-----------------------------------|---------------------------|-------|-------------------|----------|-------------------|-----------------------------------------------------------------------------|------------|
| 19  | Masalova, O. V. et al | 2010 | Female DBA/2 J mice               | Full-size NS5A protein    | IM    | thrice with a month's interval | Immunomax | Eukaryotic Cell Transfection, ELISA | Enhancement of cellular immune response, secretion of antiviral cytokines IFN-γ and IL-2 | [81]       |
| 20  | Martin, P. et al    | 2008 | HLA-A2 transgenic mice            | NS3, NS4 and NS5B proteins | IV    | twice, 2 weeks apart          | N/A      | ELISpot and CTL assays            | Induction of strong and broader IFN-γ ELISpot and CTL responses          | [13]       |
| 21  | Long, K. L. et al   | 2008 | C57BL/6 mice and monkey           | NS3/NS4A                  | IM    | Three times, 2 weeks apart in mice and two times, 4 weeks apart in the monkeys | N/A      | Immunofluorescence, ELSpot,       | Induction of strong anti-NS3/NS4A T cell responses                         | [82]       |
| 22  | Folgori, A. et al   | 2006 | Chimpanzees (Pan troglodytes)     | NS3- NS5B region          | IM    | Adenovirus injection: Two times, 4 weeks apart administered bilaterally, booster injected at week 25, plasmid DNA injection at 35, 37,39 weeks | N/A      | IFN-γ intracellular staining, cytotoxicity assay                           | High CMI in 4 out of 5 subjects, no increase of hepatic enzymes in vaccinated chimpanzees, HCV specific intrahepatic CD8 +T-cell response | [83]       |
| 23  | Li, Y. P. et al     | 2006 | B6C3F1 mice and piglets           | E2                        | ID and SC | Three times, 3 weeks apart | N/A      | CTL assay and ELISA            | Strong stimulation of strong Th1-like immune responses in mice, more balanced immune responses in piglets, production of higher E2-specific antibody levels and shifting the immune response towards Th2-like ones in piglets | [84]       |
### Table 1 (continued)

| Row | Author(s)       | Year | Host                                      | Genomic region for design | Route | Prescribed number | Adjuvant | Laboratory method                  | Efficiency                                                                 | References |
|-----|----------------|------|-------------------------------------------|---------------------------|-------|-------------------|----------|------------------------------------|---------------------------------------------------------------------------|------------|
| 24  | Ahlen, G. et al| 2005 | wild-type or CD8−/-C57BL/6 mice           | NS3/4A                    | IV    | Two times, 2 weeks apart | N/A      | SDS PAGE and Western blot         | Enhancement of T specific cells by transdermal DNA-based vaccination entered the liver and Clearance of NS3/4A-expressing hepatocytes in transiently transgenic CD8+/+ mice but not in CD8−/− mice | [85]       |
| 25  | Zhu, M. et al  | 2004 | BALB/c mice                               | E1/E2                     | quadriceps muscles | Three times, two weeks apart | CpG      | HCV antigen specific proliferation assays and cytokine secretion assays | Enhancement of humoral and cellular immune responses. CpG adjuvant significantly enhances the cellular immune response | [86]       |
| 26  | Ou-Yang, P. et al | 2002 | BALB/c mice                               | Core protein              | IM    | Two times, seven days apart | GM-CSF  | ELISA, Immunofluorescence, proliferative assay | Higher Antibody titer and cytotoxic T cell and protein expressing CD11c+ Dendritic cells | [87]       |
| 27  | Ma, X. et al   | 2002 | BALB/c (H-2d) mice                        | E2                        | IM    | Three times with a month’s interval | CpG      | ELISA and CTL assay               | superior antibody and CTL responses                                  | [88]       |

ID; intradermally; IM; intramuscularly; IV; intravenously; MPL; monophosphoryl lipid A; SC; sub-cutaneously; IP; intraperitoneally
development. They subsequently demonstrated comparable immune response following immunization using non-catalytic NS3 mutants compared to wild type NS3. Their results indicated that the comparable effectiveness and reduced bioactivity of these immunogens, would prove to be efficient alternatives to wild type HCV proteins in DNA vaccines against HCV [28]. Gene electrotransfer of a DNA vaccine encoding an optimized version of the nonstructural region of HCV (from NS3 to NS5B) also induced substantially more potent, broad, and long-lasting CD4+ and CD8+ cellular immunity than naked DNA injection in mice and in rhesus macaques, as measured by a combination of assays, including IFN-γ ELISPOT, intracellular cytokine staining, and CTL assays [17]. Furthermore, the work of Martin, P et al. revealed three epitopes mapping within the NS3 protease (GLL: aa 1038–1047) or helicase (ATL: aa 1260–1268 and TLH: aa 1617–1625) which display similar and high in vitro binding capacities to soluble HLA-A2 molecules, are capable of inducing either CTLs and/or IFN-γ-producing T cells. This peptide could recall in vitro HCV-specific IFN-γ and IL-10-producing T cells from peripheral blood mononuclear cells of chronically infected patients. These data increase the pool of NS3-specific CD8+ T-cell epitopes available to analyze HCV associated immunity and could contribute to the design and evaluation of candidate vaccines [29].

It is of note to say to that in vaccinations of chimpanzees with recombinant DNA and adenovirus expressing HCV core, E1E2, and NS3-5 genes based on HCV1b genotype, viral loads were 100 times lower than naïve infected controls and the antibody levels against E2 glycoproteins were inversely correlated with peak viral loads after intravenous challenge. Interestingly, one vaccine that had stabilizing immunity against slightly heterologous virus, generated highest level of E2-specific total and neutralizing antibody responses as well as NS3/NS5-specific T-cell proliferative responses. The other four vaccines with low levels of E2-specific antibody had about 44-fold reduced peak viral loads but eventually developed persistent infections [30].

Other studies have focused on using DNA-based vaccines utilizing multiple expression cassettes. Expression of HCV core protein regulated by an inducible in vivo-activated Salmonella promoter and HCV E2 protein by the cytomegalovirus enhancer/promoter resulted in efficient induction of HCV core and E2-specific cellular immune responses and antibodies in oral immunization of BALB/c mice with the attenuated Salmonella strain SL7207 carrying this plasmid. IgG purified from immunized mice could neutralize the infectivity of HCV pseudoparticles of both the autologous Con 1 isolate and the heterologous H77 isolate, and cell culture-produced HCV of Con1-JFH1 chimera [31]. While using multiple expression cassettes stands out as a promising modification to plasmid sequence for boosting immunity, further studies are needed to confirm their efficacy and safety.

**Multi-epitope expression**

Previous studies have shown that immunization using serial administration of multi-epitope plasmid DNAs and peptides harboring immunodominant CD8+ T cell epitopes (HLA-A2 and H2-Dd) from Core (132–142), NS3 (1073–1081) and NS5B (2727–2735), a Th CD4+ epitope from NS3 (1248–1262), and a B-cell epitope from E2 (412–426) formulated with Montanide ISA 720 adjuvant resulted in less robust immune response and HCV-specific level of total IgG, IgG1 and IgG2a in those receiving heterologous DNA/peptide and DNA/DNA compared to those receiving peptide/peptide regimen. Interestingly, IFN-γ levels in those receiving three doses of the peptide vaccines were significantly higher than those receiving two doses of the plasmid vaccine and a single dose of the peptides with Montanide ISA 720 adjuvant. Notably, the triple-dose peptide vaccine had a higher IFN-γ/IL-4 ratio compared to the other group.weeks [16]. In contrast, Masalova et al. have demonstrated that combined use of a fragmented NS3-NS5B plasmid and recombinant core, NS3, NS4, NS5A, and NS5B proteins and peptides induced statistically greater cytokine expression compared to recombinant proteins and plasmid-based immunogens alone. Furthermore, their findings demonstrated that the pcNS3–NS5B plasmid induced a more T-cell-oriented response, whereas the recombinant NS3 and NS5B proteins stimulated a potent humoral immune response [32].

Moreover, mice receiving polycistronic construct capsid/E1/E2/NS2/NS3 (pRC/C-NS3) encoding 5 structural and nonstructural proteins in a canarypox virus had enhanced antibody and cellular responses to HCV proteins. Immunodominant CD8+ T cell responses to several HCV structural and nonstructural proteins, characterized by cytotoxicity and interferon-γ production or IFN-γ production without significant cytotoxicity, were observed in both strains of mice. The combination of naked DNA with a non-replicating canarypox booster encoding HCV polycistronic pRC/C-NS3 genes appears to diversify and enhance T-cell responses to HCV proteins [33].

A multiple antigenic peptide immunization using six peptides derived from conserved epitopes in E1, E2 (n = 2), NS4B, NS5A and NS5B administered to BALB/c mice as HCVp6-multiple antigenic peptide at doses ranging from 800 ng to 16 μg resulted in humoral responses to structural epitopes, induction of IFN-γ producing
CD4+/CD8+ T-lymphocytes at extended durations i.e., >20 weeks, and viral neutralization of genotypes 2a and a chimeric 2a/4a virus in HCV culture using mice sera at > 1600 ng/animal doses for at least 20 weeks. They have shown that HCVp6–multiple antigenic peptide confers potent viral neutralization and specific cellular responses [34].

Different combinations of a candidate HCV vaccine consisting of 100 µg recombinant HCV core/E1/E2 DNA plasmid and/or 25 µg recombinant HCV polypeptide and 50 µL Montanide ISA-51 were also constructed in a previous study. IgG titers for specific HCV antibodies (total IgG, IgG1, and IgG2a), cell proliferation, and intracellular IFN-γ 4 weeks after the final injection was only assessed in mice immunized with recombinant HCV DNA plasmid, recombinant HCV polypeptide, and montanide and mice immunized with recombinant HCV polypeptide and montanide. IgG1 was the predominant antibody detected in the group receiving recombinant HCV DNA and HCV core/E1/E2 polypeptide, and montanide as well as those receiving recombinant polypeptide and montanide. However, no IgG2a response was detected in any of the groups. Proliferation assays demonstrated that splenocytes from recombinant HCV DNA primed/recombinant HCV polypeptide boost group had developed significant anti-HCV proliferative responses. The combination of a recombinant HCV DNA plasmid, recombinant HCV polypeptide, and montanide induced a high antibody titer with a predominance of IgG1 antibodies while recognizing the major neutralization epitopes in hypervariable region 1 of E2 glycoprotein [35].

BALB/c mice (H-2d restricted) vaccinated intramuscularly with a multi-CTL epitope gene consisting of two epitopes of HCV (H-2d-restricted HCV core 133–142 and E1315–322) cloned into the eukaryotic expression vector pcDNA3.1 induced CTLs against target cells (P815, H-2d restricted) pulsed with various CTL epitope peptides. Therefore, the multi-CTL epitope-based DNA vaccine directed against two HCV CTL epitopes could induce specific CTL responses to each of the two CTL epitopes independently and long-term CD8+ T-cell memory responses. The epitope-specific CTLs produced helper T-cell type 1 cytokines. [36].

Furthermore, chimpanzees immunized transdermally twice with recombinant replication competent vaccinia viruses expressing HCV genes resulted in resolution of HCV infection with the rate of chronicity between the immunized and the control animals being close to statistical significance (P = 0.067). Immunized animals developed vigorous IFN-γ enzyme-linked immunosplot responses and moderate proliferative responses [37]. To investigate cross-genotype protection, the immunized, recovered chimpanzees in the described study were challenged with a pool of six major HCV genotypes. During the acute phase after the multigenotype challenge, all animals had high-titer viremia in which genotype 4 dominated (87%), followed by genotype 5 (13%). After fluctuating low-level viremia, the viremia eventually turned negative or persisted at very low levels [37].

Optimization of prime-boost regimen

Vaccines designed as prime-boost regimens confer further protection by repeated and/or serialized exposure of viral epitopes during immunization period. Generally, the most successful protocol for DNA immunization to induce CTL responses is priming plasmid DNA to induce low-level, persistent immunity with strong but short-lived immunity of the recombinant virus boosters [38, 39]. However, the use of heterologous DNA prime–recombinant adenovirus boost regimen also had promising results.

Mice primed with either conventional pVRC-based or suicidal pSC-based DNA vaccines carrying DEC-205-targeted NS3 antigen and boosted with type 5 adenoviral vectors encoding the partial NS3 and core antigens C44P, induced a marked increase in antigen-specific humoral and T-cell responses in comparison with either recombinant Adenovirus-based vaccines or DEC-205-targeted DNA immunization in isolation. The protective effect against heterogeneous challenge was correlated with high levels of antiNS3 IgG and T-cell-mediated immunity against NS3 peptides. Moreover, prime-boosting with a suicidal DNA vaccine (pVRC-DEC-NS3), which elicited increased TNF-a-producing CD4+ and CD8+ T-cells against NS3-2 peptides (aa 1245–1461), demonstrated increased heterogeneous protection compared with priming with a conventional DNA vaccine (pVRC-DEC-NS3) [40].

Another study reporting the development of recombinant Lambda bacteriophage nanoparticles encoding HCV core antigen investigated the antigen-specific immune responses triggered in mice by different prime–boost combinations. The homologous prime/boost with recombinant Lambda nanoparticles induced higher levels of cellular and humoral immune response than the DNA vaccines. However, the protective effects of the vaccine (lymphocyte proliferation, CD8+ cytotoxic activity) was still lower than a heterologous prime immunization with HCV Core protein using DNA vaccine followed by Lambda boost, which resulted in shifting the immune response toward a Th1 pattern with a greater overall immunity [41]. A DNA-based vaccine expressing HCV genotype 1a NS3/4A proteins and a boost regimen with a modified vaccinia virus expressing genotype 1b NS3/4/5B proteins (MVATG16643) also induced significantly higher levels of IFN-γ or IL-2 ELISpot responses.
compared with each vaccine alone, independent of the time of analysis and the time interval between vaccinations. Both CD8+ and CD4+ T-cell responses as well as the spectrum of epitopes recognized were improved. A significant increase in polyfunctional IFN-γ/tumor necrosis factor α (TNF-α)/CD107a+ CD8+ T cells were detected following vaccination (from 3 to 25%), and prime/boost was the only regimen that activated quad-rifunctional T cells (IFN-γ/TNF-α/CD107a/IL-2). Incorporation of interleukin-12 (IL-12) expression in DNA plasmid also led to a highly efficient CTL induction and clearance of HCV-core expressing vaccinia virus in a triple prime-boost regimen using HCV core antigen [38]. In vivo functional protective capacity of the DNA prime/ MVA boost was also demonstrated in a Listeria-NS3-1a challenge model [42].

Noticeably, recombinant adenovirus vaccines elicited greater levels of IFN-γ secreting T-cell response and CTL response than the DNA vaccines in a study by Park, S. H et al.. However, a heterologous regimen priming DNA vaccine with a recombinant resulted in higher level of Th1 responses compared to the other regimens including double immunization with the recombinant adenovirus. Furthermore, three E2-specific CTL epitopes were mapped using a peptide pool spanning the E2 protein sequence (a.a. 384–713) in BALB/c mice, and one of these (E2 405–414: SGPSQKIQLV) was shown to be immunodominant. It is of note to say that no significant differences were found in the repertoire of E2-specific T-cell responses or in the immunodominance hierarchy of the three epitopes with different regimens, demonstrating the effectiveness of the heterologous DNA prime-recombinant adenovirus boost in conferring T-cell based immune response[43]. Triple prime-boost immunization combination with HCV core protein expression using plasmid (pcDNA3.1) and replication-defective adenovirus (Adex1SR3ST) in another study induced CTL response in mice in all but one combination in which all three immunizations were done using the plasmid vaccine [38].

Complementary strategies

While a considerable portion of the reviewed literature on HCV vaccine development focused on optimal protein and epitope selection and prime-boost combinations, a group of studies have also focused on strategies to refine adjuvants, target sequences, and vaccine delivery which could be used in tandem with the aforementioned strategies in order to boost or prolong vaccine immunogenicity.

Adjuvant selection

Previous reports have studied a variety of potential adjuvants for HCV vaccines. For instance, Levander et al. research showed that HBV core antigen (HBcAg) can act as an adjuvant in hepatitis C virus (HCV) based DNA vaccines. Addition of full-length and fragmented stork HBcAg gene sequences added to an HCV non-structural 3/4A protein gene (NS3/4A-stork-HBcAg) resulted in an enhanced priming of HCV-specific IFN-γ and IL-2 responses in both wild-type and NS3/4A transgenic mice, the latter with dysfunctional NS3/4A-specific T-cells [19]. On the other hand, Behzadi et al. have shown in their study that the use of complete Freund’s adjuvant, monophosphoryl lipid A can induce the production of Th1/Th2 cells and CD8+ T-cells in all the immunized groups [26]. Interestingly, an eccentric study on vaccine development have shown that polysaccharides derived from Artemisia annua could be utilized as an adjuvant and modulate immune response induced by a NS3 plasmid DNA vaccine by increasing IFN-γ but not antibody or IL-4, suggesting the mechanism to be the result of modulation of Th1 response [44]. Synthesized Poly(D,L- lactic acid)-co-poly(ethylene glycol)-co-poly(D,L-lactic acid) (PLA–PEG–PLA) and poly(d,l-lactic-co-glycolic acid;PLGA)–PEG–PLGA used as micelles with encapsulated plasmid pcDNA3.1 also had appealing results as adjuvants with no considerable side effects in single oral immunization with DNA/polymers with noticable immune responses in in vivo tests [45].

Heat shock protein gp96

Utilizing N-terminal domain of heat shock protein gp96 (NT(gp96)) has also been shown to be a potent adjuvant for enhancing immunity. A PT DNA vaccine studied in a previous study which encoded four HCV immunodominant CTL epitopes (two HLA-A2- and two H2-Dd-specific motifs) from the Core, E2, NS3 and NS5B antigens in addition to a T-helper CD4+ epitope from NS3 and a B-cell epitope from E2 with the NT(gp96) was fused to the C- or N-terminal end of the PT DNA (PT-NT(gp96) or NT(gp96)-PT) demonstrated that immunization of mice with PT DNA vaccine fused to NT(gp96) induced significantly stronger T-cell and antibody responses than PT DNA alone. Additionally, the adjuvant activity of NT(gp96) was more efficient in the induction of immune responses when fused to the C-terminal end of the HCV DNA polytope [21].

HBsAg and immunoglobulin Fc

Immunization with a vector harboring coding sequence of HBsAg and Hepatitis C Virus core protein in tandem within the pcDNA3.1 backbone shifted the immune responses pathway to T-helper (Th1) by enhancing the
IFN-γ cytokine level much higher than protein immunization while the proliferative and CTL responses were comparatively the same (or slightly in favor of DNA immunization) [1]. Moreover, a recombinant plasmid termed cDNA3.1-E2-Fc expressing HCV E2 with an immunoglobulin Fc fusion tag induced higher titers of E2-specific IgG in mice immunized with pcDNA3.1-E2-Fc compared to mice immunized with pcDNA3.1-E2 alone. Furthermore, pcDNA3.1-E2Fc immunization could boost E2-specific lymphocyte proliferation and enhance the secretion of IFN-γ by lymphocytes upon in vitro stimulation with soluble E2 compared to pcDNA3 [46].

Immunization of mice using several HCV epitopes (encoding; core132–142 [C], E2405–414 [E4], E2614–622 [E6] and NS31406–1415 [N]) CD8+ CTL epitopes as CE4E6N polytope) and its HbsAg-fused counterpart elicited strong CTLs and IFN-γ-secreting cells that were further augmented towards a Th1 response and partial tumor protection by DNA-prime/peptide-boosting regimen compared to the adjuvant formulated synthetic-peptide immunization. Priming with HbsAg alone could not explain the augmenting effect of the vaccine, indicating the importance of priming by polytope itself.

Several other studies have also investigated the modulation of immune response against HCV immunogens using HBV antigens. Co-Administration of DNA Vaccine Encoding HBV Surface Antigen and HCV Envelope Antigen in BALB/c mice resulted in antibody production against both HBV and HCV and increased expression of IL-2 and RANTES but not IL-4, and therefore, inducing a Th1 response [47]. Furthermore, immunization of C57BL/6 mice with plasmid DNA expressing five fragments of HCV E2 fused to HbsAg gene was accompanied by an IgG2a-dominant antibody production against both proteins in mice sera and high IFN-γ expression in cultured splenic cells [48]. Hence, fusion of immune carriers like HbsAg conjoined with DNA-prime/peptide-boost immunization regimen is a feasible strategy to enhance the epitope-specific immune responses towards poly-CTL-epitopic vaccines [49].

Perforin
Coexpression of PRF, a pore forming protein released by CD8 T-cells and NK cells, and HCV antigens on a single plasmid elicits strong cell mediated immunity against the HCV NS proteins (3, 4A, 4B, and 5B) [50]. The results of the same study evaluating the vaccine demonstrated that encoding the NS4A protein in a vaccine which encoded only NS3 counterintuitively reduced the immunogenicity of NS3, while addition of PRF increased NS3 immunogenicity. On the other hand, the inclusion of NS4A in a PRF-encoding DNA vaccines increased the immunogenicity of the NS3, NS4B, and NS5B proteins [50]. Furthermore, a truncated mouse PRF with cytolytic activity lacking the final 12 amino acids of the C terminus was used instead of the full-length protein [51], which was also determined to be more immunogenic than the respective canonical DNA vaccine lacking PRF. DNA-based vaccines using pNS3-PRF, pNS4/5-PRF, pNS3/4/5B plasmids could elicit robust long-term cell mediated immunity evidenced by high reactogenicity with Interferon-γ enzyme-linked immunosorbent spot (ELISpot) assay against HCV peptides. The multi-antigenic vaccine primed with PRF promoted cytolytic vaccination without any adverse side-effects in mice [52]. The mechanisms for the higher immunogenicity generated by PRF could be explained by the study conducted by Grubor-Bauk et al. They examined the mechanism of cell death by the bicistronic DNA vaccine encoding the HCV NS3 and PRF under the control of CMV and SV40 promoters, respectively. The results of the study showed that the inclusion of perforin in the DNA vaccine altered the fate of NS3-positive cells from apoptosis to necrosis, and resulted in more robust immune responses in mice and pigs [20].

GM-CSF
The conflicting results of the previous studies, precludes decisive judgement on inclusion of GM-CSF in HCV DNA vaccines. In contrast to some of the previous works such as the one from Masalova O. V., et al. who showed pcGM-CSF increase humoral and cellular immune response [32], Chen et al. demonstrated that co-inoculated GM-CSF causes significant suppression to the dengue virus type 1 and type 2 prM-E DNA vaccinations and influences protective efficiency against virus challenge. Counterintuitively, GM-CSF showed little or no effect on the immune response elicited by hepatitis C virus C or E1 DNA vaccine candidates. Notably, these effects of GM-CSF were long-lasting [53]. Moreover, co-vaccination of DNA encoding GM-CSF and Flt-3 ligand together with a plasmid encoding for the HCV NS5 protein induced increased antibody responses and CD4+ T cell proliferation to this protein. Vaccination with DNA encoding GM-CSF and Flt-3L promoted protection against tumor formation and/or reduction in mice co-immunized with cytokine-encoding DNA constructs [54].

Macrophage inflammatory protein 3-beta
Macrophage inflammatory protein 3-beta gene added as an adjuvant in a triple-dose HCV core DNA vaccine elicited an enhanced Th1 biased systemic immune response as evidenced by higher IFN-γ/ IL-4 and anti-core IgG2a/ IgG1 ratio, lymphoproliferation, strong cytolytic GrzB release and enhanced population of IFN-γ producing
immunocytes. Likewise, the humoral immune response assumed as the total anti-core IgG level was augmented by Macrophage inflammatory protein 3-beta co-delivery [55]. Similarly, mice co-immunized with a CCL20-containing plasmid developed higher levels of core specific IFN-γ/IL-4 ratio and IL-2 release, IFN-γ producing cells, lymphocyte proliferation and cytotoxic Granzyme B release in both draining lymph nodes and spleen cells of immunized mice. The core-specific serum total IgG and IgG2a/IgG1 ratio were significantly higher when the pCCL20 was co-inoculated [22].

**Listeriolysin O**

Pouriaevally et al. introduced Listeriolysin O of Listeria monocytogenes (toxin with an extremely immunogenic feature) as an attractive adjuvant. They have shown that introduction of NS3 and Listeriolysin O gene induced the highest titer of total IgG against NS3 antigen compared with other controls. Determination of IgG subclasses confirmed an effective increase in mixed responses with Th1dominancy. In addition, significant levels of cytokines (P < 0.05) and lymphocyte proliferation responses (P < 0.05) indicated the superiority of this regimen. The findings may have important implication for Listeriolysin O gene application as genetic adjuvant in immune response against HCV [56].

**IFN-λ3**

Addition of IFN-λ3 to a plasmid encoding NS3-NS5A also increased IFN-γ spot-forming cells and both CD4+ and CD8+ T cell subsets produced multiple cytokines. However, the frequency and phenotype of HCV-specific MHC-I dextramer +CD8+ T cells were not changed. Interestingly, the frequency of Treg cells, particularly activated Treg cells, was decreased which was in line with previous reports indicating that IFN-λ3 adjuvants decrease Treg cell frequency. Ex vivo IFN-λ3 treatment similarly reduced Treg frequency in pre-vaccination peripheral blood mononuclear cells. Finally, Treg cell frequency inversely correlated with HCV-specific, IFN-γ-producing T cell responses in the study participants [57].

**Modification of signal sequence**

Injection of plasmids encoding full-length E2 and non-structural protein 1 (p7) fused to either 13 or 38 C-terminal amino acids (aa) of HCV E1 or a complete E1 stop-transfer signal with duplicated second hydrophobic segment resulted in potent antibody production against E2/p and T-helper cell response targeted against hypervariable region 1, aa 472–586 of E2, and a novel epitope at aa 774–796 of p7. Profile of cytokines secreted by proliferating mouse splenocytes stimulated in vitro with E2- and p7-derived peptides, indicated mixed Th1/Th2 type of immune response. Thus, the full-length E2 and p7 genes supplied in one cassette modulated the immunogenic profile of E2. E2/p7 containing a complete E1 stop-transfer signal with prolonged membrane spanning domain was superior to the shorter E2/p7 version in terms of both antibody and cellular immunogenicity. Thus, optimal performance of HCV E2 could be achieved through modification of the E2 signal sequence, the release of E2 from the rough ER while retaining full-length E2 and p7 sequences, improving TH2 performance of HCV envelope genes as prototype vaccine [58].

**CpG adjuvants and plasmid enrichment**

Yu et al. showed that a plasmid enriched with 24 CpG motifs (pBISIA24-NS3) tends to induce a strongest and consistent Th1-biased immune response. Subsequently, it was shown that NS3 formulated with CpG oligodeoxynucleotide and Quil A (rNS3+CpG+Quil A) adjuvants induces a balanced immune response in mice, compared to recombinant NS3 combined with either CpG or QuilA which elicit a Th2-biased response. To further enhance NS3-specific cell-mediated immune responses, a vaccination regime consisting of priming with pBISIA24-NS3, followed by boosting with rNS3+CpG+Quil A, was explored in mice and pigs. In contrast to immunization with rNS3+CpG+Quil A, this regimen shifted the immune response to a Th1-type response and, accordingly, enhanced MHC I-restricted killing by CTL in mice. Although immunization with pBISIA24-NS3 also induced a Th1-biased response, including cytototoxicity in the mice, the humoral response was significantly lower than that induced by the DNA prime–protein boost regime [59].

**Utilization of co/post translational modification**

In a recent study by Masavuli et al. incorporation of secreted E1 and E2 (sE1 and sE2) into oligomers by fusion with the oligomerization domain of the C4b-binding protein, IMX313P resulted in increased effectiveness in eliciting humoral and cell-mediated immunity against the envelope proteins. Further boosting with recombinant E1E2 proteins but not DNA nor virus-like particles expressing E1E2 increased the immunogenicity of the DNA prime-boost regimen. However, antibodies generated by the homologous DNA prime-boost vaccinations more effectively inhibited the binding of virus-like particles to target cells and neutralized transduction with HCV pseudoparticles derived from different genotypes including genotypes 1, 2, 3, 4, 5, and 6 [60].

Analysis of immunogenicity of wild type E1E2, five N-glycosylation sites-mutated E1E2 glycoproteins, and
five CpG-coupled E1E2 N-glycosylation-mutated glycoproteins in BALB/c mice showed that deletion of N-glycans can enhance viral immunogenicity and the CpG-coupled DNA vaccine mutant elicted increased CD4+ Th1 and CD8+ T cell responses and neutralizing antibody production against HCV infection [61].

Modification of N-linked glycosylation of HCV E1 protein, a naturally poor immunogen, through site-directed mutagenesis of N-linked glycosylation sites in plasmids containing the genes for both wild type and mutant E1 in BALB/C mice resulted in enhanced E1-specific CTL activities, expression of IFN-γ producing T cells, and suppression of tumor growth E1-M2 mutant (at site of N576ST) compared to control. IgG2a/IgG1 ratios were elicited in a Th1-type response. There-fore, modulation of the N-glycosylation site N576ST of E2-M2 mutant (at N576ST) close to these regions were mutated separately or in combination led to significantly higher E2-specific CTL response, IgG2a/IgG1 ratios, expression of IFN-γ, and suppression of tumor growth (P < 0.05) with the E2-M2 mutant (at N576ST) compared to control. IgG2a/IgG1 ratios were elicited in a Th1-type response. Therefore, modulation of the N-glycosylation site N576ST of HCV E2 protein may enhance specific cellular immune response and could be utilized in the development of E2-based DNA vaccines with enhanced immunogenicity [62].

In addition, immunization with plasmids containing genes encoding either wild type or mutant E2 proteins with mutated N-glycosylation sites (N560NT and N576ST) close to these regions were mutated separately or in combination led to significantly higher E2-specific CTL response, IgG2a/IgG1 ratios, expression of IFN-γ, and suppression of tumor growth (P < 0.05) with the E2-M2 mutant (at N576ST) compared to control. IgG2a/IgG1 ratios were elicited in a Th1-type response. Therefore, modulation of the N-glycosylation site N576ST of HCV E2 protein may enhance specific cellular immune response and could be utilized in the development of E2-based DNA vaccines with enhanced immunogenicity [63].

Discussion

Successful induction of immune response against transduced antigen proteins in the early 1990s introduced the concept of DNA immunization into the scientific spotlight [64]. Nucleic acid vaccines have been proven since then to be a safe platform to elicit protective humoral and cellular immune response to a variety of infectious agents and diseases as well as therapeutic modalities to treat malignancies and autoimmune disorders [64–66].

Compared to classic non-live vaccines, nucleic acid-based vaccines could be easily mass produced and can readily stimulate humoral and, particularly cellular immune responses in preclinical studies, which is favorable for immunization against viral infections such as HCV. Furthermore, they do not carry the risk of transmitting active infection in immunocompromised individuals as seen with live attenuated vaccines while similarly mimicking live infection [64, 67]. As such, DNA vaccines would be optimal candidates to induce strong and protective CD4+ T-cell and CTL response early on in HCV infections, where viral clearance is closely associated with virus-specific T cell immunity [68, 69]. Nevertheless, the suboptimal immunogenicity and anti-vector immunity observed in first generation DNA vaccines in primates has highlighted the need for strategies to enhance the immune response as described in this review [51].

While this systematic review attempted to cover studies on RNA vaccines in HCV, the initial database search revealed no studies fitting the inclusion and exclusion criteria, reflecting the lack of adoption of widespread RNA platform in vaccine HCV design. Although the initial concerns regarding instability and large-scale manufacturing of RNA halted the widespread adoption of RNA vaccines, the promising aspects of this type of vaccines such as the ability to express a variety of antigens with high efficiency while having no risk of integrating exogenous DNA into host genome, has made them an attractive alternative to DNA vaccines [67, 70]. The preliminary reports on mass vaccination with SARS-CoV-2 mRNA vaccines have demonstrated their general safety and high efficacy in disease prevention [71]. Therefore, with proper backbone, RNAs encoding HCV antigens [72] could obviate the need for electroporation to generate sufficient immune response and demonstrate higher efficacy and immunogenicity compared to DNA vaccines.

This review summarized recent original researches on the topic of HCV DNA vaccines and discussed the strategies on optimization of HCV DNA vaccines and their efficiency. Based on the reviewed literature, the authors suggest that incorporation of multiple viral proteins or their epitopes in a homologous or heterologous prime-boost regimen or using CpG-enriched DNA and recombinant virus vaccines with coexpression of potent adjuvants with high immunogenicity are valid strategies to increase the potency of potential vaccines. Considering the limited efficacy of the results of the registered clinical trials with candidate vaccines [73, 74], future studies show focus on maximizing the immunogenicity of their vaccines by incorporating the strategies mentioned throughout this text.

Abbreviations

HCV: Hepatitis C virus; CTL: Cytotoxic T lymphocyte; HBV: Hepatitis B virus; IL: Interleukin; PRF: Perforin; CCL20: CC-chemokine ligand 20; GM-CSF: Granulocyte-monocyte colony stimulating factor; NS: Hepatitis C non-structural protein; IFN-γ: Interferon-γ; ELISpot: Interferon-γ enzyme-linked immunosorbent spot; Th: T helper.
Acknowledgements

None.

Authors’ contributions

AS, RK, and SA conducted the systematic search and contributed to drafting the manuscript. PH and MA evaluated and screened the data. MHY and TH contributed to data curation. SHM conceptualized and supervised the study. SA and SHM revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Funding

This work was conducted in absence of any funding from organizations or individuals.

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no known competing interests.

Author details

1Student Research Committee, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran. 2Department of Medical Virology, Tarbiat Modares University, Tehran, Iran. 3Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. 4Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran. 5Hepatitis Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran. 6Department of Clinical Laboratory Sciences, School of Allied Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran. 7Department of Infectious Disease, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran. 8Shiraz HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran. 9Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran. 10Department of Microbiology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.

Received: 16 August 2021 Accepted: 26 November 2021

Published online: 13 December 2021

References

1. Yazdanian M, Memarnejadian A, Mahdavi M, Motevalli F, Sadat SM, Vahabpour R, Khanahmad H, Soleimanjahi H, Budkowska A, Roohvand F. Evaluation of cellular responses for a chimeric HBsAg-HCV core DNA vaccine in BALB/c mice. Adv Biomed Res. 2015;4:13.
2. Mohamadi M, Azarbayjani K, Mozghani S-H, Bamdad T, Alamdary A, Nikoo HR, Hashempour T, Hedaya Yaghoobi M, Ajoofoo M. Hepatitis C virus alternative reading frame protein (ARFP): Production, features, and pathogenesis. J Med Virol. 2020;92(2):2930–7.
3. Mohdr Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–42.
4. Rongeard P, Beaumont E. Hepatitis C vaccine: 10 good reasons for continuing. Hepatology. 2020;71(1):1845.
5. Wu J, Zhou Y, Fu X, Deng M, Zheng Y, Tian G, Li Y, Wang C, Ding C, Ruan B. The burden of chronic hepatitis C in China from 2004 to 2050: an individual-based modeling study. Hepatology. 2019;69(4):1442–52.
6. Ayoub HH, Al Kanaani Z, Abu-Raddad LJ. Characterizing the temporal evolution of the hepatitis C virus epidemic in Pakistan. J Viral Hepatitis. 2018;25(6):670–9.
7. Kanwal F, Kramer J, Asch SM, Chayanupatmatikul M, Cao Y, El-Seraf HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153(4):996–1005.e1001.
8. Li D, Huang Z, Zhong J. Hepatitis C virus vaccine development: old challenges and new opportunities. Natl Sci Rev. 2015;2(3):285–95.
9. Bailey JR, Barnes E, Cox ALIG. Approaches, progress, and challenges to hepatitis C virus vaccine development. 2019;156(2):418–30.
10. Lindenbach BD. Measuring HCV infectivity produced in cell culture and in vivo. In: Hepatitis C edn.: Springer; 2009: 329–336.
11. Stoll-Keller F, Barth H, Fafi-Kremer S, Zeisel MB, Baumert TF. Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines. 2009;8(3):333–45.
12. Pouriajeavali MH, Bamdad T, Aghasadeghi MR, Sadat SM, Sabahi F: Construction and immunogenetics analysis of hepatitis C virus (HCV) truncated non-structural protein 3 (NS3) plasmid vaccine. Jundishapur Journal of Microbiology 2016, 9(3).
13. Martin P, Simon B, Lone VC, Chate L, Barry R, Inchauspe G, Fourniller A. A vector-based minigenic vaccine approach results in strong induction of T-cell responses specific of hepatitis C virus. Vaccine. 2008;26(20):2471–81.
14. Dueñas Carrera S, Alvarez-Lajonchere L, Alvarez-Oregón JC, Pérez A, Acosta-Rivero N, Vázquez DM, Martínez G, Viña A, Pichardo D, Morales J. Enhancement of the immune response generated against hepatitis C virus envelope protein proteins after DNA vaccination with polyprotein-encoding plasmids. Biotechnol Appl Biochem. 2002;35(5):205–12.
15. Deng Y, Zhang K, Tan W, Wang Y, Chen H, Wu X, Ruan L. A recombinant DNA and vaccinia virus prime-boost regimen induces potent long-term T-cell responses to HCV in BALB/c mice. Vaccine. 2009;27(15):2085–8.
16. Pishraft-Sabet L, Taheri T, Memarnejadian A, Mokhtari Azad T, Asgari F, Rahimnia R, Alavian SM, Rafati S, Samimi Rad K. Immunogenicity of Multi-Epitope DNA and Peptide Vaccine Candidates Based on Core, E2, NS3 and NS5B HCV Epitopes in BALB/c Mice. Hepatitis Month. 2014;41(10)e22215.
17. Capone S, Zampaglione I, Vitelli A, Pezzanera M, Kierstead L, Burns J, Ruggeri L, Arcuri M, Cappellitti M, Meola A, et al. Modulation of the immune response induced by gene electroporation of a hepatitis C virus DNA vaccine in nonhuman primates. J Immunol. 2006;177(10):7462–71.
18. Enckle J, Radzun W, Eisenbach C, Geib J, Gehrike S, Piëff E, Stremmel W. Development of a heterologous, multigenotype vaccine against hepatitis C virus infection. Eur J Clin Invest. 2007;37(5):396–406.
19. Lederer S, Sallberg M, Ahlen G, Frelini L. A non-human hepapnavirus adjuvant for hepatitis C virus-based genetic vaccines. Vaccine. 2016;34:2821.
20. Grubor-Bauk B, Yu W, Wijesundara D, Gummow J, Garrod T, Brennan AJ, Voskoboinik I, Gowans EJ. Intradermal delivery of DNA encoding HCV NS3 and perforin elicits robust cell-mediated immunity in mice and pigs. Gene. 2016;523(1):26–37.
21. Pishraft-Sabet L, Kosinska AD, Rafati S, Bolhasani A, Taheri T, Memarnejadian A, Alavian SM, Roggendorf M, Samimi-Rad K. Enhancement of HCV polytope DNA vaccine efficacy by fusion to an N-terminal fragment of heat shock protein gp96. Adv Virol. 2015;2015(3):140.
22. Hartoonian C, Sepehrizadeh Z, Mahdavi M, Arashkia A, Jang YS, Ebteteck M, Yazdi MT, Negahdari B, Nikoo A, Azadmanesh K. Modulation of hepatitis C virus core DNA vaccine immune responses by co-immunization with CC-chemokine ligand 20 (CCL20) gene as immunoadjuvant. Mol Biol Rep. 2014;41(1):5943–52.
23. Naderi M, Sadeghi A, Moradi A, Keshadi M, Zolfaghari MR, Gorji A, Ghaemi A. Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicity. Virologica Sinica. 2013;28(3):167–73.
24. Hartoonian C, Ebteteck M, Soleimanjahi H, Karami A, Mahdavi M, Rastgoo N, Azadmanesh K. Effect of immunological adjuvants: GM-CSF (granulocyte-monocyte colony stimulating factor) and IL-23 (interleukin-23) on immune responses generated against hepatitis C virus core DNA vaccine in vivo. In: Hepatitis C edn.: Springer; 2009: 329–336.
25. Frelin L, Alheim M, Chen A, Soderholm J, Rozell B, Barnfield C, Liljestrom P. Development of a heterologous, multigenotype vaccine against hepatitis C virus infection. Eur J Clin Investig. 2018;25(6):670–9.
27. Ahlen G, Soderholm J, Tjelle T, Kjeken R, Frelin L, Moglund U, Blomberg P, Fons M, Mathiesen J, Sallberg M. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3A/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD34+ cells. J Immunol (Baltimore, Md: 1950). 2007;179(7):4741–53.

28. Ratnoglik SL, Jiang DP, Aoki C, Sudarmono P, Shiogi J, Deng L, Hotta H. Induction of cell-mediated immune responses in mice by DNA vaccines that express hepatitis C virus NS3 mutants lacking serine protease and NTPase/RNA helicase activities. PLoS ONE. 2014;9(6):e98877.

29. Martin P, Parroche P, Chatel L, Barretto C, Beck A, Trepo C, Bain C, Lone YC, Ratnoglik SL, Jiang DP, Aoki C, Sudarmono P, Shoji I, Deng L, Hotta H. Immunogenicity of multiepitope antigen vaccine of HCV carried by novel biodegradable polymers. Comp Immunol Microbiol Infect Dis. 2011;34(1):65–72.

30. Youn JW, Park SH, Laviellette D, Cosset FL, Yang SH, Lee CG, Jin HT, Kim CM, Shata MT, Lee DH, et al. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology. 2005;42(6):1429–36.

31. Cao J, Chen Z, Ren Y, Luo Y, Cao M, Lu W, Zhao P, Qi Z. Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice. Vaccine. 2011;29(20):3714–23.

32. Masalova OV, Lesnova EI, Permyakova KY, Ivanov AV, Tunitskaya VL, Kushch AA. Enhancement of the immune response by codelivery of hepatitis C virus recombinant DNA and proteins of the replicative complex. Mol Genet Microbiol. 2015;30(1):39–47.

33. Pancholi P, Liu Q, Tricocco N, Pei Z, Perkus ME, Prince AM. DNA prime-canarypox boost with polyclonal hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins. J Infect Dis. 2000;182(1):18–27.

34. Dawood RM, Moustafa RI, Abdelhafedz EH, El-Senawry W, El-Abd Y, El Din NG, Dubuisson J, El Awady MK. A multipeptide peptide vaccine against HCV stimulates neutralizing humoral and persistent cellular responses in mice. 2019;19(1):932.

35. Ghorbani M, Naiss T, Azi A, Soare C, Aucoin S, Giulivi A, Anderson DE, Diaz-Mitoma F. Comparison of antibody- and cell-mediated immune responses after intramuscular hepatitis C immunizations of BALB/c mice. Viral Immunol. 2005;18(4):637–48.

36. Shi L, Liu S, Fan GX, Liu M, Chi L, Zhao P, Zhang XL. N-glycosylation-mutated hepatitis C virus envelope glycoprotein complex enhances antigen-presenting activity in mice. J Immunol. 2008;183(8):4768–75.

37. Youn JW, Hu YW, Tricocco N, Pfahler W, Shata MT, Dreux M, Cosset FL, Folgori A, Lee DH, Brotman B, et al. Evidence for protection against type 1 cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmid. Vaccine. 2003;21(15):1629–39.

38. Estcourt MJ, Ramsay AJ, Brooks A, Thomson SA, Medveckzy CJ, Ramshaw P, Fons M, Mathiesen I, Sallberg M. In vivo electroporation enhances the local DNA uptake, protein expression, inflammation, and infiltration of CD34+ cells. J Immunol (Baltimore, Md: 1950). 2006;176(4):702–11.

39. Gummow J, Masavuli MG, Mekonnen ZA, Gowans EJ, Grubor-Bauk B. Cytolytic perfom as a adjuvant to enhance the immuno- genicity of DNA vaccines. Vaccines. 2019;7(2):38.

40. Guan J, Deng Y, Chen H, Gao N, Wu J, Zheng X, Liu J, Fan D, et al. Variable effects of the co-administration of a GM-CSF-expressing plasmid on the immune response to flavivirus DNA vaccines in mice. Immunol Lett. 2015;162(1):140–8.

41. Han JW, Sung PS, Hong SH, Lee H, Koh JY, Lee H, White S, Maslow JN, Weiner DB, Park SH, et al. IFNL3-adjuvanted HCV DNA vaccine reduces potency of hepatitis C virus NS3 DNA vaccine. 2019, 71(10):1645–1652.

42. Hartoonian C, Sepehrizadeh Z, Tabatabai Yazdi M, Jang YS, Langrudi L, Amir Kalkanagh P, Negahdari B, Karami A, Ebteler M, Azadmanesh K. Enhancement of Immune Responses by Co-delivery of CCL19/ILP-3beta Chemokine Plasmid With HCV Core DNA/Protein Immunization. Hepatitis monthly. 2014, 14(3):e14611.

43. Nam SH, Park JH, Kang JH, Kang SY, Kim JH, Kim SY, Ahn J, Park KS, Chung HJ. Modulation of immune response induced by co-administration of DNA vaccine encoding HBV surface antigen and HCV envelope antigen in BALB/c mice. Arch Pharmaco. Res. 2006;29(11):1042–7.

44. Jin J, Yang JY, Liu J, Kong YY, Yang W, Li GD. DNA immunization with fusion genes encoding different regions of hepatitis C virus E2 fused to the gene for hepatitis B surface antigen elicits immune responses to both HCV and HBV. World J Gastroenterol. 2002;8(3):505–10.

45. Min YQ, Liu M, Chi L, Zhao P, Zhang XL. N-glycosylation-mutated hepatitis C virus envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses. Biochem Biophys Acta. 2015;1860:1764.

46. Liu M, Chen H, Luo F, Li P, Pan Q, Xia B, Qi Z, Ho WZ, Zhang XL. Deletion of N-glycosylation sites of hepatitis C virus envelope protein E1.
enhances specific cellular and humoral immune responses. Vaccine. 2007;25(36):6572–80.
63. Li P, Wan Q, Feng Y, Liu M, Wu J, Chen X, Zhang X-L. Engineering of N-glycosylation of hepatitis C virus envelope protein E2 enhances T cell responses for DNA immunization. Vaccine. 2007;25(38):1544–51.
64. Kurtzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet. 2008;9(10):776–88.
65. Silva CL, Bonato VLD, dos Santos-Júnior RR, Zárate-Bladés CR, Sartori A. Recent advances in DNA vaccines for autoimmune diseases. Expert Rev Vaccines. 2009;8(2):239–52.
66. Yang B, Jeang J, Yang A, Wu TC, Hung CF. DNA vaccine for cancer immuno-therapy. Hum Vaccin Immunother. 2014;10(11):13153–64.
67. Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA vaccines for infectious diseases. Front Immunol. 2019;10:594.
68. Swadling L, Capone S, Antrobus Richard D, Brown A, Richardson R, Newell Evan W, Halliday J, Kelly C, Bowen D, Ferguson J, et al. A human vaccine strategy based on chimpanzee adenoviral and DNA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Science Transl Med. 2014;6(261):153–261.
69. Thimme R. T cell immunity to hepatitis C virus: Lessons for a prophylactic vaccine. J Hepatol. 2021;74(1):220–9.
70. Ulmer JB, Geall AJ. Recent innovations in mRNA vaccines. Curr Opin Immunol. 2016;41:18–22.
71. Baden LR, El Sahly HM, Essink B, Lalezari P, Li J, Mauer S, et al. A synthetic codon-optimized hepatitis C virus nonstructural 5A (NS5A) induces the effective cellular immune response. Mol Biol. 2013;46(261):153–261.
72. Sharifi S, Keshavarz M, Karimi Z, Zarghami N. Design and development of modified mRNA encoding core antigen of hepatitis C virus: a possible application in vaccine production. Iran Biomed J. 2019;23(1):57–67.
73. Sepulveda-Crespo D, Resino S, Martinez I. Hepatitis C virus vaccine design: focus on the humoral immune response. J Biomed Sci. 2020;27(1):78.
74. Page K, Melia MT, Veenhuis RT, Winter M, Rousseau KE, Massaccesi G, Osburn WC, Forman M, Thomas E, Thornton K. Randomized trial of a vaccine regimen to prevent chronic HCV infection. N Engl J Med. 2021;384(5):403–16.
75. Lee H, Jeong M, Oh J, Cho Y, Shen X, Stone J, Yan J, Rothkopf Z, Khan AS, Cho BM, et al. Preclinical evaluation of multi antigenic HCV DNA vaccine for the prevention of Hepatitis C virus infection. Sci Rep. 2017;7(1):43531.
76. Ahlen G, Holmstrom F, Gibbs A, Alheim M, Feinlin L. Long-term functional duration of immune responses to HCV NS3/4A induced by DNA vaccination. Gene Ther. 2014;21(8):739–50.
77. Gorzin Z, Gorzin AA, Tabarraei A, Behnampour N, Irani S, Ghaemi A. Immunogenicity evaluation of a DNA vaccine expressing the hepatitis C virus non-structural protein 2 gene in C57BL/6 mice. Iran Biomed J. 2014;18(1):1–7.
78. Wada T, Kohara M, Yasutomi Y. DNA vaccine expressing the non-structural proteins of hepatitis C virus diminishes the expression of HCV proteins in a mouse model. Vaccine. 2013;31(50):5968–74.
79. Holmstrom F, Pasetto A, Nehr V, Brass A, Kriegs M, Hildet E, Broderick KE, Chen M, Ahlén G, Feinlin L. A synthetic codon-optimized hepatitis c virus nonstructural 5A DNA vaccine primes polyfunctional CD8+ T Cell responses in wild-type and NS5A-transgenic mice. J Immunol. 2013;190(3):1113–24.
80. Park SH, Song MY, Nam HM, Im SJ, Sung YC. Codelivery of IL-7 Augments Multigenic HCV DNA Vaccine-Induced Antibody as well as Broad T Cell Responses in Cynomolgus Monkeys. Immune network. 2010;10(6):198–205.
81. Masalova OV, Lesnaya EV, Grabovetskii VV, Smirnova OA, Ulanova TI, Burkov AN, Ivanov AV, Zaberezhnyi AD, Ataulakhanov RI, Kushner AA. DNA immunization with a plasmid containing gene of hepatitis C virus protein 5A (NS5A) induces the effective cellular immune response. Mol Biol. 2010;44(2):275–83.
82. Lang KA, Yan J, Dragha-Aiki R, Khan A, Weiner DB. Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine. 2008;26(49):6225–31.
83. Folgori A, Capone S, Ruggeri L, Meola A, Sporen E, Ercole BB, Pezzanera M, Tafi R, Arcuri M, Fattori E. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med. 2006;12(2):190–7.
84. Li YP, Kang HN, Babiku LA, Liu Q. Elitication of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models. World J Gastroenterol. 2006;12(44):7126–35.
85. Ahlen G, Nystrom J, Pult J, Feinlin L, Hultgren C, Sallberg M. In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes. J Infect Dis. 2005;192(12):2112–6.
86. Zhu LX, Liu J, Ye Y, Xie YH, Kong YY, Li GD, Wang Y. A candidate DNA vaccine elicits HCV-specific humoral and cellular immune responses. World J Gastroenterol. 2004;10(17):2488–92.
87. Ou-Yang P, Huang LH, Tao MH, Chiang BL, Chen DS. Co-delivery of GM-CSF gene enhances the immune responses of hepatitis C viral core protein-expressing DNA vaccine: role of dendritic cells. J Med Virol. 2002;66(3):320–8.
88. Ma X, Form X, Gutiérrez R, Mushahwar IK, Wu T, Payette PJ, Bukh J, Purcell RH, Davis HL. DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. Vaccine. 2002;20(27–28):3263–71.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.